Short Divalent Ethacrynic Amides As Pro-inhibitors of Glutathione -transferase Isozyme Mu and Potent Sensitisers of Cisplatin-resistant Ovarian Cancers

Overview

Journal J Enzyme Inhib Med Chem

Specialty Biochemistry

Date 2022 Feb 18

PMID 35176963

Authors

Bangtian Xu

Tingting Tong

Xin Wang

Fang Liu

Xiang Zhang

Xiaolei Hu

Xinpeng Li

Xiaolan Yang

Fei Liao

Affiliations

Soon will be listed here.

Abstract

The linking of ethacrynic acid with ethylenediamine and 1,4-butanediamine gave EDEA and BDEA, respectively, as membrane-permeable divalent pro-inhibitors of glutathione -transferase (GST). Their divalent glutathione conjugates showed subnanomolar inhibition and divalence-binding to GSTmu (GSTM) (PDB: 5HWL) at ∼0.35 min. In cisplatin-resistant SK-OV-3, COC1, SGC7901 and A549 cells, GSTM activities probed by 15 nM BDEA or EDEA revealed 5-fold and 1.0-fold increases in cisplatin-resistant SK-OV-3 and COC1 cells, respectively, in comparison with the susceptible parental cells. Being tolerable by HEK293 and LO2 cells, BDEA at 0.2 μM sensitised resistant SK-OV-3 and COC1 cells by ∼3- and ∼5-folds, respectively, released cytochrome c and increased apoptosis; EDEA at 1.0 μM sensitised resistant SK-OV-3 and A549 cells by ∼5- and ∼7-fold, respectively. EDEA at 1.7 μg/g sensitised resistant SK-OV-3 cells to cisplatin at 3.3 μg/g in nude mouse xenograft model. BDEA and EDEA are promising leads for probing cellular GSTM and sensitising cisplatin-resistant ovarian cancers.

Citing Articles

Overexpression of Glutathione S-Transferases in Human Diseases: Drug Targets and Therapeutic Implications.

Lv N, Huang C, Huang H, Dong Z, Chen X, Lu C Antioxidants (Basel). 2023; 12(11).

PMID: 38001822 PMC: 10668987. DOI: 10.3390/antiox12111970.

GRP75-faciliated Mitochondria-associated ER Membrane (MAM) Integrity controls Cisplatin-resistance in Ovarian Cancer Patients.

Li J, Qi F, Su H, Zhang C, Zhang Q, Chen Y Int J Biol Sci. 2022; 18(7):2914-2931.

PMID: 35541901 PMC: 9066115. DOI: 10.7150/ijbs.71571.

References

Rotili D, De Luca A, Tarantino D, Pezzola S, Forgione M, Morozzo Della Rocca B . Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases. Eur J Med Chem. 2014; 89:156-71. DOI: 10.1016/j.ejmech.2014.10.033. View

Clipson A, Bhat V, McNae I, Caniard A, Campopiano D, Greaney M . Bivalent enzyme inhibitors discovered using dynamic covalent chemistry. Chemistry. 2012; 18(34):10562-70. DOI: 10.1002/chem.201201507. View

Li K, Chen B, Xu L, Feng J, Xia G, Cheng J . Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo. Int J Nanomedicine. 2013; 8:1867-77. PMC: 3656817. DOI: 10.2147/IJN.S43752. View

Maeda D, Mahajan S, Atkins W, Zebala J . Bivalent inhibitors of glutathione S-transferase: the effect of spacer length on isozyme selectivity. Bioorg Med Chem Lett. 2006; 16(14):3780-3. DOI: 10.1016/j.bmcl.2006.04.041. View

Singh R, Reindl K . Glutathione S-Transferases in Cancer. Antioxidants (Basel). 2021; 10(5). PMC: 8146591. DOI: 10.3390/antiox10050701. View

Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

Chatterjee A, Gupta S . The multifaceted role of glutathione S-transferases in cancer. Cancer Lett. 2018; 433:33-42. DOI: 10.1016/j.canlet.2018.06.028. View

Williams J, Morrison J . The kinetics of reversible tight-binding inhibition. Methods Enzymol. 1979; 63:437-67. DOI: 10.1016/0076-6879(79)63019-7. View

Zou M, Hu X, Xu B, Tong T, Jing Y, Xi L . Glutathione S‑transferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer. Oncol Rep. 2018; 41(2):989-998. DOI: 10.3892/or.2018.6861. View

10.

Tew K, Monks A, Barone L, Rosser D, Akerman G, Montali J . Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Mol Pharmacol. 1996; 50(1):149-59. View

11.

Mammen M, Choi S, Whitesides G . Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. Angew Chem Int Ed Engl. 2018; 37(20):2754-2794. DOI: 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3. View

12.

McCoy A, Grosse-Kunstleve R, Adams P, Winn M, Storoni L, Read R . Phaser crystallographic software. J Appl Crystallogr. 2009; 40(Pt 4):658-674. PMC: 2483472. DOI: 10.1107/S0021889807021206. View

13.

Federici L, Sterzo C, Pezzola S, Di Matteo A, Scaloni F, Federici G . Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione s-transferases. Cancer Res. 2009; 69(20):8025-34. DOI: 10.1158/0008-5472.CAN-09-1314. View

14.

Caffrey P, Frenkel G, McAndrew K, Marks K . A Model of the Development of Cisplatin Resistance in Human Small Cell Lung Cancer Xenografts. In Vivo. 2016; 30(6):745-749. DOI: 10.21873/invivo.10990. View

15.

Morgan A, Ciaccio P, Tew K, Kauvar L . Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother Pharmacol. 1996; 37(4):363-70. DOI: 10.1007/s002800050398. View

16.

Rossmann M, van Beek C . Data processing. Acta Crystallogr D Biol Crystallogr. 1999; 55(Pt 10):1631-40. DOI: 10.1107/s0907444999008379. View

17.

Koehler R, Villar H, Bauer K, Higgins D . Ligand-based protein alignment and isozyme specificity of glutathione S-transferase inhibitors. Proteins. 1997; 28(2):202-16. DOI: 10.1002/(sici)1097-0134(199706)28:2<202::aid-prot9>3.0.co;2-g. View

18.

Buist H, van Burgsteden J, Freidig A, Maas W, van de Sandt J . New in vitro dermal absorption database and the prediction of dermal absorption under finite conditions for risk assessment purposes. Regul Toxicol Pharmacol. 2010; 57(2-3):200-9. DOI: 10.1016/j.yrtph.2010.02.008. View

19.

Stoddard E, Killinger B, Nair R, Sadler N, Volk R, Purvine S . Activity-Based Probes for Isoenzyme- and Site-Specific Functional Characterization of Glutathione S-Transferases. J Am Chem Soc. 2017; 139(45):16032-16035. PMC: 6279235. DOI: 10.1021/jacs.7b07378. View

20.

Lo H, Ali-Osman F . Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol. 2007; 7(4):367-74. DOI: 10.1016/j.coph.2007.06.009. View